Video

HER2CLIMB: Sequencing in Metastatic Breast Cancer

Related Videos
Alberto Montero, MD
Stephanie L. Graff, MD
Stephanie L. Graff, MD
5 experts are featured in this series
Laura A. Huppert, MD
Polly Niravath, MD
Charles E. Geyer, Jr., MD
Alexis LeVee, MD
Related Content
Polly Niravath, MD
January 15th 2025

Clinical, Molecular Factors Correlate With pCR for Durvalumab/Trastuzumab/Pertuzumab in Early HER2+ Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Ian Krop, MD, PhD, director, Clinical Trials Office, chief clinical research officer, associate director, clinical sciences, Yale Cancer Center; professor, internal medicine (medical oncology), Yale School of Medicine
January 14th 2025

Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Kelly K. Hunt, MD, FACS, FSSO, of MD Anderson Cancer Center
January 3rd 2025

One Surgeon’s Spirit and Brilliance Lift a Whole Community

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies